Two major populations of circulating T lymphocytes can be defined serologically. Leu 2a, OKT5 and OKT8 identify the suppressor/cytotoxic (CD8) subset and Leu 3a, 3b and OKT4 the helper/inducer (CD4) subpopulation. A reduction in number or percentage of OKT5 and T8 cells has been reported'-7 but also disclaimed"' in patients with multiple sclerosis, although results are more consistent using the Leu 2a antibody. [12] [13] [14] Monoclonal antibodies can be used singly or in combination to identify less heterogenous lymphocyte populations including those characterised by the presence of activation markers expressed transiently during T cell maturation.'"'9 Within the CD8 subset, suppressor and cytotoxic cells can be distinguished using Leu 2a and Leu 15 in combination'5 and activated CD8 cells may be identified by dual labelling with Leu 2a and anti-DR. '6 Suppressor inducer (CD4: OKT4/2H4 positive) lymphocytes which in turn stimulate the suppressor (CD8: Leu 2a/1 5) subpopulation are reduced in patients with chronic progressive multiple sclerosis."7 Impaired T suppressor function correlates with the OKT4/2H4 but not CD8 phenotype'7 20123; the likely explanations are first that the CD8 antigen is present on cells other than T suppressor lymphocytes, and secondly that non-specific functional suppressor assays involve a complex interaction ofB, T helper and suppressor cell responses to plant mitogens.
There is an increase in T cells expressing early and late activation markers in patients with multiple sclerosis;"24-28 some of these antigens are present on activated T helper/inducer (CD4) and cytotoxic/suppressor (CD8) lymphocytes whereas the expression of others is not confined to T lymphocytes at all.
In order to define the contribution of fluctuations in suppressor cells to 
Results
Our previously reported results demonstrated a reduction in mean percentage of OKT8 cells in multiple sclerosis patients and cohabitant relatives, but not in non-cohabitant siblings or unrelated controls. 29 In the present study the percentage ofcryopreserved Leu 2a cells was also reduced in samples from six multiple sclerosis patients and five cohabitant relatives compared with four non-cohabitants and seven controls (table) . This reduction in CD8 lymphocytes, defined either by OKT8 or Leu 2a was associated with lower percentages of Leu 2a/1 5 positive cells in multiple sclerosis patients than cohabitants, non-cohabitants or controls. The Leu 2a/DR subpopulation did not differ between groups. Leu 3a/3b identified a lower percentage of circulating CD4 cells than OKT4. This difference was significant in cohabitant and non-cohabitant relatives but the T4 or Leu 3a/3b phenotype did not differ between groups.
Using all results available from each participant, there was a strong correlation between Leu 2a phenotype and OKT8 positive cells (r = 0-87: p < 0-001); each also correlated with Leu 2a/15 positive cells (r = 0-79: p < 0-001 and r = 0-63: p < 0-01 respectively). The percentage of Leu 3a/3b cells correlated with OKT4 phenotype (r = 0-64, p < 0-01). It may be statistically invalid to treat every sample from each individual separately since there is an a priori expectation of one abnormal result following another. However, a significant correlation between Leu 2a and OKT8 positive cells, and between Leu 2a and Leu 2a/ 15 
